Prostate Specific Antigen News and Research

RSS
Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Shared decision policies lead to high rates of PSA testing and inequity with minimal benefit

Shared decision policies lead to high rates of PSA testing and inequity with minimal benefit

UC San Diego Health offers a new minimally invasive biopsy procedure to detect prostate cancer

UC San Diego Health offers a new minimally invasive biopsy procedure to detect prostate cancer

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

Why men should eat more plants: the effect of mediterranean plant-forward diets on health

Why men should eat more plants: the effect of mediterranean plant-forward diets on health

Researchers estimate the environmental impacts of prostate MRI and biopsy

Researchers estimate the environmental impacts of prostate MRI and biopsy

Enhanced prediction of prostate cancer recurrence using machine learning model

Enhanced prediction of prostate cancer recurrence using machine learning model

Declining PSA levels predict improved survival rates in men with non-metastatic castration-resistant prostate cancer

Declining PSA levels predict improved survival rates in men with non-metastatic castration-resistant prostate cancer

New blood test can detect prostate cancer with greater accuracy than current methods

New blood test can detect prostate cancer with greater accuracy than current methods

New nanotechnology-based test can detect and profile prostate cancers even in microscopic amounts

New nanotechnology-based test can detect and profile prostate cancers even in microscopic amounts

Hormonal therapy may aid in reducing progression of early-stage prostate cancer during active surveillance

Hormonal therapy may aid in reducing progression of early-stage prostate cancer during active surveillance

PSMA PET/MRI can successfully determine the risk of prostate cancer recurrence

PSMA PET/MRI can successfully determine the risk of prostate cancer recurrence

Study shows the prevalence of low-value prostate cancer screening in primary care clinics

Study shows the prevalence of low-value prostate cancer screening in primary care clinics

Rising Medicare costs linked to increased use of new prostate cancer therapies

Rising Medicare costs linked to increased use of new prostate cancer therapies

Cambridge scientists develop a comprehensive tool for predicting individual's risk of prostate cancer

Cambridge scientists develop a comprehensive tool for predicting individual's risk of prostate cancer

Study identifies risk factors that increase Black men's susceptibility to early-onset prostate cancer

Study identifies risk factors that increase Black men's susceptibility to early-onset prostate cancer

Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancer

Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancer

Polygenic hazard score could be effective for predicting genetic risk of lethal prostate cancer

Polygenic hazard score could be effective for predicting genetic risk of lethal prostate cancer

$38,398 for a single shot of a very old cancer drug

$38,398 for a single shot of a very old cancer drug

More intensive prostate cancer screening may reduce the risk of metastatic cancer later

More intensive prostate cancer screening may reduce the risk of metastatic cancer later

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.